Invivyd, Inc. 8-K

What Happened

• On April 9, 2026, Invivyd, Inc. (NASDAQ: IVVD) filed a Current Report on Form 8-K (Item 8.01) and issued a press release titled “Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles.”
• The filing also includes a corporate presentation; the press release and presentation are attached as Exhibits 99.1 and 99.2 to the 8-K.

Key Details

• Date of filing and release: April 9, 2026.
• Program and candidate named: REVOLUTION program; measles monoclonal antibody candidate VMS063.
• Characterization used by the company: VMS063 described as a “novel, potential first- and best-in-class” candidate for treatment and prevention of measles.
• Materials filed with the SEC: Press release (Ex. 99.1) and corporate presentation (Ex. 99.2).

Why It Matters

• The 8-K informs investors that Invivyd is advancing a new measles antibody program (VMS063) and is publicly communicating program progress. Such pipeline updates highlight the company’s R&D focus and may be relevant to investors tracking clinical, regulatory, or commercialization milestones.
• The filing does not report clinical data, financial results, regulatory approvals, or new timelines—investors should watch for future company releases that provide data, trial starts, or regulatory updates.